Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 8/20 | 0.43 |
| ▸ | HTR7 | P34969 | 8/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874840 | 0.84 | DPP4 (0.49) | DPP4VNN1HTR1AHTR7ACE | |
| SCHEMBL13570397 | 0.84 | DPP4 (0.49) | DPP4VNN1HTR1AHTR7ACE | |
| SCHEMBL30874873 | 0.78 | VNN1 (0.43) | DPP4VNN1HTR1AHTR7ACE | |
| SCHEMBL30874798 | 0.78 | VNN1 (0.62) | DPP4VNN1ACE | |
| SCHEMBL30874862 | 0.76 | CYP19A1 (0.47) | DPP4VNN1HTR1AHTR7ACE | |
| SCHEMBL30874874 | 0.76 | VNN1 (0.44) | DPP4VNN1HTR1AHTR7ACE | |
| SCHEMBL30874909 | 0.76 | VNN1 (0.47) | DPP4VNN1HTR1AHTR7DPP9 | |
| SCHEMBL2177077 | 0.76 | DPP4 (0.57) | DPP4HTR1AHTR7ACE | |
| SCHEMBL474918 | 0.76 | DPP4 (0.57) | DPP4HTR1AHTR7ACE | |
| SCHEMBL30874914 | 0.75 | DPP4 (0.44) | DPP4HTR1AHTR7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | DPP4 3092/4885VNN1 3398/4885HTR1A 2664/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | DPP4 3092/4885VNN1 3398/4885HTR1A 2664/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | DPP4 3310/4885VNN1 2957/4885HTR1A 3724/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | DPP4 3092/4885VNN1 3398/4885HTR1A 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.